Edmond Kwan

A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy.

Christian Daniel Fankhauser, Ben Tran, Manuel Pedregal, José Manuel Ruiz-Morales, Egon Gonzalez-Billalabeitia, Anna Patrikidou, Eitan Amir, Christoph Seidel, Carsten Bokemeyer, Thomas Hermanns, Alexey Rumyantsev, Alexey Tryakin, Margarida Brito, Aude Fléchon, Edmon M Kwan, Tina Cheng, Daniel Castellano, Xavier Garcia Del Muro, Anis A Hamid, Margaret Ottaviano, et al.

Journal article  |  2020  |  European Urology Focus

BACKGROUND: It remains unclear which patients with metastatic germ cell tumours (mGCTs) need prophylactic anticoagulation to preve..

Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease

Andrew Schmidt, Angelyn Anton, Julia Shapiro, Shirley Wong, Arun Azad, Edmond Kwan, Lavinia Spain, Arun Muthusamy, Javier Torres, Phillip Parente, Francis Parnis, Jeffrey Goh, Anthony M Joshua, David Pook, Peter Gibbs, Ben Tran, Andrew Weickhardt

Journal article  |  2020  |  Asia-Pacific Journal of Clinical Oncology

AIM: Optimal treatment for newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) has evolved, with many patients de..

Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression

Edmund Lau, Patrick McCoy, Fairleigh Reeves, Ken Chow, Michael Clarkson, Edmond M Kwan, Kate Packwood, Helen Northen, Miao He, Zoya Kingsbury, Stefano Mangiola, Michael Kerger, Marc A Furrer, Helen Crowe, Anthony J Costello, David J McBride, Mark T Ross, Bernard Pope, Christopher M Hovens, Niall M Corcoran

Journal article  |  2020  |  Genome Medicine: medicine in the post-genomic era

BACKGROUND: DNA originating from degenerate tumour cells can be detected in the circulation in many tumour types, where it can be ..

Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer

Heidi Fettke, Edmond M Kwan, Maria M Docanto, Patricia Bukczynska, Nicole Ng, Lisa-Jane K Graham, Kate Mahon, Christine Hauser, Winston Tan, Xiao Hong Wang, Zhixin Zhao, Tiantian Zheng, Kemin Zhou, Pan Du, Jianjun Yu, Yong Huang, Shidong Jia, Manish Kohli, Lisa G Horvath, Arun A Azad

Journal article  |  2020  |  European Urology

BACKGROUND: The androgen receptor (AR) remains a critical driver in metastatic castration-resistant prostate cancer (mCRPC). Profi..

Analytical validation of an error-corrected ultra-sensitive ctDNA next-generation sequencing assay.

Heidi Fettke, Jason A Steen, Edmond M Kwan, Patricia Bukczynska, Shivakumar Keerthikumar, David Goode, Maria Docanto, Nicole Ng, Luciano Martelotto, Christine Hauser, Melissa C Southey, Arun A Azad, Tu Nguyen-Dumont

Journal article  |  2020  |  BioTechniques

Plasma circulating tumor DNA (ctDNA) analysis has emerged as a minimally invasive means to perform molecular tumor typing. Here we..

Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor-treated Metastatic Castration-resistant Prostate Cancer.

Heidi Fettke, Edmond M Kwan, Patricia Bukczynska, Nicole Ng, Tu Nguyen-Dumont, Melissa C Southey, Ian D Davis, Andrew Mant, Phillip Parente, Carmel Pezaro, Christine Hauser, Arun A Azad

Journal article  |  2020  |  European Urology Focus

Total plasma cell-free DNA (cfDNA) levels were recently shown to be prognostic in two large phase III trials of taxane chemotherap..

Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. PRO: docetaxel chemotherapy should be the default consideration in metastatic hormone-sensitive prostate cancer.

Edmond M Kwan, Arun A Azad

Journal article  |  2020  |  Current Opinion in Urology

Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?

Amanda Pereira-Salgado, Edmond Michael Kwan, Ben Tran, Peter Gibbs, Johann De Bono, Maarten IJzerman

Journal article  |  2020  |  European Urology Focus

CONTEXT: Optimal treatment sequencing of abiraterone and enzalutamide in chemotherapy-naïve metastatic castration-resistant prosta..

Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer

Manish Kohli, Winston Tan, Tiantian Zheng, Amy Wang, Carlos Montesinos, Calven Wong, Pan Du, Shidong Jia, Siddhartha Yadav, Lisa G Horvath, Kate L Mahon, Edmond M Kwan, Heidi Fettke, Jianjun Yu, Arun A Azad

Journal article  |  2020  |  EBioMedicine

BACKGROUND: Metastatic prostate cancer is a clonally heterogeneous disease state characterized by progressive somatic perturbation..

Navigating systemic therapy for metastatic castration-naive prostate cancer

EM Kwan, IA Thangasamy, J Teh, O Alghazo, NJ Sathianathen, N Lawrentschuk, AA Azad

Journal article  |  2020  |  World Journal of Urology